Stock Information

• VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
  Tue, Mar 24, 2026 4:12 PM
• Pfizer CFO Dave Denton Highlights Firm’s Recent Oncology Milestones
  Tue, Mar 24, 2026 3:02 PM
• Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
  Tue, Mar 24, 2026 2:52 PM
• Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook
  Tue, Mar 24, 2026 2:39 PM
• Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
  Tue, Mar 24, 2026 2:00 PM
• Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday
  Tue, Mar 24, 2026 9:40 AM
• Guggenheim Maintains Buy on Pfizer, Raises Price Target to $36
  Tue, Mar 24, 2026 7:34 AM
• Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story
  Mon, Mar 23, 2026 11:06 PM
• Pfizer Stock Is Doing Something It Hasn't Done Since 2022
  Mon, Mar 23, 2026 8:20 PM
• Pfizer-Valneva Lyme disease vaccine falls short as low cases skew results
  Mon, Mar 23, 2026 6:31 PM

Financial data not available